Bone metastases identified

Asymptomatic, incidentally detected

Further research is required to determine whether preventive therapy with zoledronic acid or the targeted receptor activator of nuclear factor-kB (RANK) ligand inhibitor denosumab may be of value for preventing development of skeletal-related events (SREs) in NETs.

Use of zoledronic acid or denosumab in asymptomatic, incidental cases remains controversial and should be considered on a case-by-case basis after discussion with patient.

**Denosumab is slightly more effective in preventing skeletal morbidity (at least in other solid tumours), easier to administer and avoids renal monitoring. However, needs to be given every month whereas zoledronic acid can be given 3 monthly, is 10x more expensive and difficult to discontinue due to rebound osteolysis.**

Symptomatic

Multidisciplinary management integrating expertise in systemic treatments, radiotherapy, orthopaedic surgery, and supportive care is required for effective treatment of metastatic bone disease.

Current standard of care for supportive care/pain management applies.

Analgesic effect of bone-modifying agents (BMAs) [denosumab, zoledronic acid] are modest, and should not be used alone for bone pain.

A BMA is recommended for patients with metastatic NET and evidence of bone destruction.

One BMA is not recommended over another (mechanism of action, as well as potential benefit/harm should be considered).

Treatment of hypercalcaemia should follow institutional guidelines.

Orthopaedic surgery to be considered in appropriate cases.

Radiotherapy is treatment of choice for palliation of localised bone pain.

If evidence of metastatic spinal cord compression, follow institutional guidelines for management of same.

All patients should have dental examination and preventive dentistry before using a BMA.

BMAs for metastatic bone disease should continue indefinitely and throughout course of disease, if appropriate.

Optimal frequency and duration of therapy is extrapolated from studies on other types of solid tumours.
Bone metastases occurred in 25% of all phaeochromocytomas and paragangliomas (25 out of 100), 20% of high grade neuroendocrine carcinomas (9 out of 46), 9% of carcinoid tumours (30 of 341), and 8% of pancreatic NETs (12 of 153).

A multi-institutional study in the US (2004-2008) [part of collaboration with the National Comprehensive Cancer Network (NCCN) Oncology Outcomes database] identified 82 patients out of 691 (12%) with a diagnosis of a neuroendocrine tumour (NET) who developed bone metastases.

Of the 82 patients with bone metastases, 59% were reported to be symptomatic at time of detection.

Among the patients who were asymptomatic at detection, 21% went on to develop a skeletal-related event.

Pain from bone metastases is a cause of impaired performance status and psychological distress among patients with cancer.

Bone metastases from NETs have unique features on radiological and nuclear imaging, and may be missed by conventional radiography.

Currently, there is no consensus regarding the management of bone metastases from NETs, and guidance has to be extrapolated from studies conducted in other solid tumours.
References


Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R et al. (2013) NCCN Task Force Report: Bone Health in Cancer Care. 11: (Supplement 3) S1-S51.


With special thanks to Prof. Rob Coleman for his invaluable input, and to Charlotte Fribbens for reviewing Feb 2024.